

20. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. *Cancer Res* 2002; 62 (13): 3609-14.
21. Petricoin EF, 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. *J Natl Cancer Inst* 2002; 94 (20): 1576-8.
22. Li J, White N, Zhang Z, Rosenzweig J, Mangold LA, Partin AW, et al. Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. *J Urol* 2004; 171 (5): 1782-7.
23. Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. *Lung Cancer* 2003; 40 (3): 267-79.
24. Poon TC, Hui AY, Chan HL, Ang IL, Chow SM, Wong N, et al. Prediction of liver fibrosis and cirrhosis in chronic Hepatitis B infection by serum proteomic fingerprinting: A pilot study. *Clin Chem* 2004; 51: 328-35.
25. Zhu XD, Zhang WH, Li CL, Xu Y, Liang WJ, Tien P. New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDI protein chip technology. *World J Gastroenterol* 2004; 10 (16): 2327-9.
26. Hortin GL, Jortani SA, Ritchie JC, Jr., Valdes R, Jr., Chan DW. Proteomics: a new diagnostic frontier. *Clin Chem* 2006; 52 (7): 1218-22.
27. Diamandis EP. Serum proteomic profiling by Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry for cancer diagnosis: next steps. *Cancer Res* 2006; 66 (11): 5540-1.
28. Bons JA, Wodzig WK, van Dieijen-Visser MP. Protein profiling as a diagnostic tool in clinical chemistry: a review. *Clin Chem Lab Med* 2005; 43 (12): 1281-90.
29. Linke T, Ross AC, Harrison EH. Profiling of rat plasma by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, a novel tool for biomarker discovery in nutrition research. *J Chromatogr A* 2004; 1043 (1): 65-71.
30. Bons JA, de Boer D, van Dieijen-Visser MP, Wodzig WK. Standardization of calibration and quality control using surface enhanced laser desorption ionization-time of flight-mass spectrometry. *Clin Chim Acta* 2006; 366: 249-56.
31. Plebani M. Proteomics: the next revolution in laboratory medicine? *Clin Chim Acta* 2005; 357 (2): 113-22.
32. Westgard JO, Groth T, Aronsson T, de Verdier CH. Combined Shewhart-cusum control chart for improved quality control in clinical chemistry. *Clin Chem* 1977; 23 (10): 1881-7.
33. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, et al. Evaluation of serum protein profiling by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. *Clin Chem* 2005; 51 (1): 102-12.
34. Lee SW, Lee KI, Kim JY. Revealing urologic diseases by proteomic techniques. *J Chromatogr B Analyt Technol Biomed Life Sci* 2005; 815 (1-2): 203-13.
35. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. *Clin Cancer Res* 2004; 10 (3): 860-8.
36. Jock CA, Paulauskis JD, Baker D, Olle E, Bleavins MR, Johnson KJ, et al. Influence of matrix application timing on spectral reproducibility and quality in SELDI-TOF-MS. *Biotechniques* 2004; 37: 30-2, 4.
37. Cordingley HC, Roberts SL, Tooke P, Armitage JR, Lane PW, Wu W, et al. Multifactorial screening design and analysis of SELDI-TOF ProteinChip array optimization experiments. *Biotechniques* 2003; 34: 364-5, 8-73.

*Ned Tijdschr Klin Chem Labgeneesk* 2007; 32: 93-95

## Serum markers in breast cancer: are they of value and will they get better?

M.J. DUFFY

Available serum markers for breast cancer include CA 15-3, BR 27.29 (also known as CA27.29), CEA, tissue polypeptide antigen (TPA), tissue polypeptide specific antigen (TPS) and the shed form of HER-2. Of these, the most widely used are CA 15-3 and CEA (for review, see refs 1, 2). The aim of this presentation is to discuss the present and likely future use of serum markers in breast cancer.

### Screening/Aiding early diagnosis

Lack of sensitivity and specificity preclude the use of all existing serum markers for the early detection of breast cancer. Women with apparently localized breast

cancer who present with a high preoperative marker level (e.g., 5-10 times the upper limit of normal) are likely to have advanced disease (3) and should undergo appropriate investigations to diagnose or exclude this possibility.

### Determining prognosis

A number of studies have shown that elevated preoperative levels of either CA 15-3 or CEA are associated with poor outcome in patients with breast cancer (1). For example, in our study on 600 newly diagnosed breast cancer patients, the prognostic impact of preoperative CA 15-3 levels was independent of tumour size and lymph node status (4). Importantly, the prognostic value of CA 15-3 was also observed in lymph node-negative patients, the subgroup of breast cancer patients in which new prognostic factors are most urgently needed.

---

Correspondence: prof. dr. Michael J. Duffy, clinical chemist. Dept. of Nuclear Medicine, St. Vincent's University Hospital, Dublin 4, Ireland  
E-mail: micheal.j.duffy@ucd.ie

Compared to tissue prognostic factors, serum markers have a number of advantages. Firstly, unlike tumour tissue which requires either biopsy or surgery, blood can be obtained with minimal inconvenience. Secondly, automated, relatively cheap and standardized assays are available for serum markers. Thirdly, serum-based markers can be determined in patients with small tumours including those with in situ cancers. For tissue-based markers, especially if freshly-frozen tissue is necessary, patients with very small tumours cannot be assessed.

### **Surveillance following surgery**

Following surgery for breast cancer, it is now common practice to follow-up patients on a regular basis with clinical examination, radiology and tumour marker determinations. This practice is based on the belief that the early detection of recurrent or metastatic disease improves the chance of cure or results in an improved survival. From a biological point of view, it might be expected that the early detection of recurrent disease followed by the initiation of therapy would improve outcome compared with starting therapy when recurrence/metastasis is clinically evident. There is however little evidence available to support this hypothesis.

Serial determinations of markers such as CA 15-3 and CEA have the potential to detect recurrent breast cancer in asymptomatic women with median lead-times of 4-5 months (1, 3). Since it is unclear whether knowing this lead-time enhances outcome, guidelines vary in their recommendations regarding the use of tumour markers in postoperative surveillance in breast cancer. For example, the American Society of Oncology, the European Society of Medical Oncology and the European Society of Mastology recommend that serum markers should not be used in the routine surveillance of patients following primary treatment for breast cancer (3, 5, 6, 7). In contrast, the European Group on Tumour Markers (EGTM) and the National Academy of Clinical Biochemistry (NACB) recommend the use of markers during follow-up (8, 9).

### **Monitoring therapy in advanced disease**

Following the commencement of therapy for advanced disease, it is important to know as soon as possible if the patient is responding to the treatment. If the patient is benefiting, clearly treatment should be continued. If on the other hand, treatment is not effective, an alternative therapy might be given. If an alternative therapy is unavailable, these patients could be willing to participate in clinical trials or they could decide to avoid further therapy.

A convenient and relatively inexpensive approach for helping to establish response is by measuring serum markers such as CA 15-3 or CEA. Generally, decreasing marker levels correlate with tumour response while increasing markers levels correlate with tumour regression (10-12). According to the EGTM guidelines (8), markers should be measured prior to every chemotherapy course and at least three monthly intervals for patients receiving hormone therapy. The

EGTM defines an increase in marker concentration of at least 25% to be significant (8). It is recommended that such an increase be confirmed with a second specimen obtained within a month. If the increase is confirmed, this provides evidence of progressive disease. Similarly, a confirmed decrease in serum levels of more than 50% was stated to be consistent with tumour regression (8).

In contrast to the EGTM recommendations, the ASCO guidelines state that neither CA 15-3 nor CEA should be routinely used for monitoring therapy in patients with advanced breast cancer (17, 23). However, this panel also stated "that in exceptional circumstances such as the presence of osseous metastasis, which are difficult to evaluate clinically, the marker level may be able to support the clinical estimate of disease status. However, the marker cannot in any situation stand alone to define response to treatment" (3, 6).

The European Society of Mastology (EUSOMA) also recommend against the general use of serum markers for monitoring therapy in advanced breast cancer (7). However, as with the ASCO guidelines, the EUSOMA guidelines stated that "in the absence of evaluable disease, increase in tumour marker accompanied by an increase in symptoms (e.g., bone pain) should be taken as indicating disease progression". Also, according to these guidelines, "an increase in serum markers without symptoms of progression should prompt a complete work-up to investigate for progression of known disease sites or appearance of new sites" (7).

### **Potential new markers for breast cancer**

A desirable property of a serum marker is organ-specificity. None of the available serum markers for breast cancer is breast-specific as all can be elevated in serum from patients with most types of adenocarcinoma, especially in patients with advanced disease (1).

In recent years however, a number of proteins have been described that are expressed almost exclusively in breast tissue including breast cancer. These include, mammaglobin A (10-13), lipophilin B (14-15), NY-BR-1 (16,17), B726P (18), and small breast epithelial mucin (SBEM) (19). The challenge now is to devise sensitive and specific assays for measuring these proteins in serum and then evaluate their clinical value in breast cancer.

### **Will serum markers for breast cancer get better?**

As mentioned above, the main problem with all existing serum markers for breast cancer is lack of sensitivity for early disease and lack of specificity for breast cancer. Clearly, new markers must offer improved sensitivity and specificity. One of the most promising approaches in this respect is the use of proteomics. In recent years a number, a number of preliminary reports claimed to be able to detect breast cancer with sensitivities and specificities of 85-95% (for review, see ref.. 20). These findings however, will require extensive validation before they can be used clinically. Finally, if the relatively breast-

specific proteins mentioned above could be detected in serum, they also have the potential to provide a new generation of serum markers for breast cancer.

#### References

1. Duffy MJ. Serum tumour markers in breast cancer: are they of clinical value. *Clin Chem* 2006; 52: 345-351.
2. Cheung K, Graves CRL, Robertson JFR. Tumour marker measurements in the diagnosis and monitoring of breast cancer. *Cancer Treat Rev*. 2000; 26: 91-102.
3. Anonymous. Clinical practice guidelines for the use of tumour markers in breast and colorectal cancer. *J Clin Oncol* 1996; 14: 2843-2877.
4. Duffy MJ, Duggan C, Keane R, et al. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. *Clin Chem* 2004; 50: 559-563.
5. Bast RC, Ravdin P, Hayes DF, et al. 2000 Update of recommendations for the use of tumour markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. *J Clin Oncol* 2001; 19: 1865-1878.
6. Blamey RW. Guidelines on endocrine therapy of breast cancer, EUSOMA. *Eur J Cancer* 2002;38:615-634.
7. Pestalozzi BC, Luporsi-Gely E, Jost LM, et al. ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. 2005; 16 (Suppl 1): 7-9
8. Molina R, Barak V, van Dalen A, Duffy MJ, et al. Tumour markers in breast cancer: European Group of Tumour Markers (EGTM) recommendations. *Tumour Biol* 2005; 26: 281-293.
9. Fleisher M, Dnistrian AM, Sturgeon CM, et al. Practice guidelines and recommendations for use of tumour markers in the clinic. In: Diamindis EP, Fritsche H, Scharwitz MK, Chan DW, eds, *Tumour markers, physiology, pathobiology, technology and clinical applications*, Chicago: AACCC Press 2002: 33-63.
10. Robertson JFR, Jaeger W, Szymendera JJ, et al. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. *Eur J Cancer* 1999; 35: 47-53.
11. van Dalen A, Heering KJ, Barak V et al. Treatment response in metastatic breast cancer: a multicenter study comparing UICC criteria and tumour marker changes. *The Breast* 1996; 5: 82-88.
12. Kurebayashi J, Nishimura R, Tanaka K, et al. Significance of serum tumour markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study. *Breast Cancer* 2004; 11: 389-395.
13. Watson MA, Dintzis S, Darrow CM, et al. Mammaglobin expression in primary, metastatic, and occult breast cancer. *Cancer Res* 1999; 59: 3028-31.
14. Jiang Y, Harlocker SL, Molesh DA, et al. Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays. *Oncogene* 2002; 21: 2270-82.
15. O'Brien N, Maguire TM, O'Donovan N, et al. Mammaglobin a: a promising marker for breast cancer. *Clin Chem* 2002; 48: 1362-4.
16. Colpitts TL, Billing-Medel P, Friedman P, et al. Mammaglobin is found in breast tissue as a complex with BU101. *Biochemistry* 2001; 40: 11048-11059.
17. Houghton RL, Dillon DC, Molesh DA, et al. Transcriptional complementarity in breast cancer: application to detection of circulating tumour cells. *Mol Diagn* 2001; 6: 79-91.
18. Miksicek, R J, Y. Myal Y, Watson PH, et al. Identification of a novel breast- and salivary gland-specific, mucin-like gene strongly expressed in normal and tumour human mammary epithelium. *Cancer Res* 2002; 62: 2736-40.
19. Bertucci F, Birnbaum D, Goncalves A. Proteomics of breast cancer: principles and clinical applications. *Mol Cell Proteomics* 2006 Oct; 5 (10): 1772-86.
20. Colpitts TL, Billing P, Granados. E, et al. Identification and immunohistochemical characterization of a mucin-like glycoprotein expressed in early breast cancer. *Tumour Biol* 2002; 23: 263-278.

*Ned Tijdschr Klin Chem Labgeneesk* 2007; 32: 95-98

## Diagnosis and treatment of thyroid cancer: a view from the Dutch consensus

T.P. LINKS

Thyroid cancer is a rare cancer, with an incidence of 1/100,000 in men and 3/100,000 in women. This results in about 350 new patients every year in the Netherlands.

For the overall survival is good, the prevalence is relatively high 1/4000, resulting in about 4000 patients in the Netherlands (1). Histologically several subtypes of malignant thyroid tumours can be distinguished: the differentiated (papillary, follicular and Hürthle)

carcinoma originating from the follicular epithelium, the medullary carcinoma consisting of malignant transformed C cells, and the anaplastic carcinoma, often considered to represent the terminal stage in the dedifferentiation of a thyroid tumour.

Recently, it has been reported that the incidence of thyroid cancer has been increased with 2.4 fold in the United States, but the overall mortality has been remained stable. This increase is attributable to the increase of small papillary thyroid cancers, reflecting early detection or subclinical disease (2).

#### Treatment of thyroid cancer

Surgery is the cornerstone of treatment, When an uni-

---

Correspondence: dr T.P. Links, internist endocrinologist. Department of Endocrinology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen  
E-mail: t.p.links@int.umcg.nl